Richard A. Heyman Sells 817 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN) Director Richard A. Heyman sold 817 shares of the firm’s stock in a transaction dated Friday, October 18th. The shares were sold at an average price of $30.00, for a total value of $24,510.00. Following the sale, the director now directly owns 123,673 shares in the company, valued at approximately $3,710,190. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Enliven Therapeutics Stock Up 0.4 %

Shares of ELVN stock opened at $28.98 on Wednesday. The company’s fifty day simple moving average is $24.38 and its two-hundred day simple moving average is $22.84. Enliven Therapeutics, Inc. has a 52 week low of $9.80 and a 52 week high of $30.03. The stock has a market cap of $1.36 billion, a P/E ratio of -15.02 and a beta of 1.10.

Enliven Therapeutics (NASDAQ:ELVN) last announced its quarterly earnings results on Tuesday, August 13th. The company reported ($0.41) EPS for the quarter, beating analysts’ consensus estimates of ($0.58) by $0.17. On average, analysts anticipate that Enliven Therapeutics, Inc. will post -1.98 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reissued a “buy” rating and set a $37.00 target price on shares of Enliven Therapeutics in a research note on Tuesday, October 1st.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. Janus Henderson Group PLC raised its stake in Enliven Therapeutics by 74.8% during the first quarter. Janus Henderson Group PLC now owns 713,911 shares of the company’s stock valued at $12,604,000 after purchasing an additional 305,397 shares in the last quarter. First Turn Management LLC bought a new stake in shares of Enliven Therapeutics in the 2nd quarter worth about $9,657,000. Marshall Wace LLP purchased a new stake in shares of Enliven Therapeutics during the 2nd quarter valued at about $4,489,000. Baker BROS. Advisors LP bought a new position in shares of Enliven Therapeutics in the 1st quarter valued at about $2,020,000. Finally, Bank of New York Mellon Corp grew its position in Enliven Therapeutics by 49.2% in the second quarter. Bank of New York Mellon Corp now owns 114,109 shares of the company’s stock worth $2,667,000 after acquiring an additional 37,632 shares in the last quarter. 95.08% of the stock is owned by hedge funds and other institutional investors.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.